Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $8.89 USD
Change Today -0.27 / -2.95%
Volume 99.2K
ALDX On Other Exchanges
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

aldeyra therapeutics inc (ALDX) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/28/15 - $13.50
52 Week Low
08/4/14 - $3.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

aldeyra therapeutics inc (ALDX) Related Businessweek News

No Related Businessweek News Found

aldeyra therapeutics inc (ALDX) Details

Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the research and development of products for the treatment of immune-mediated, inflammatory, orphan, and other diseases in the United States. It is involved in the development of NS2, an eye drop formulation product candidate designed to trap and allow for the disposal of free aldehydes, which has completed Phase I clinical trial; and for the treatment of Sjögren-Larsson Syndrome and noninfectious anterior uveitis. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is based in Lexington, Massachusetts.

6 Employees
Last Reported Date: 05/14/15
Founded in 2004

aldeyra therapeutics inc (ALDX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $377.5K
Chief Financial Officer and Treasurer
Total Annual Compensation: $135.0K
Chief Operating Officer
Total Annual Compensation: $322.7K
Compensation as of Fiscal Year 2014.

aldeyra therapeutics inc (ALDX) Key Developments

Aldeyra Therapeutics, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2015

Aldeyra Therapeutics, Inc. reported unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company's loss from operations was $2,108,535 compared to $1,244,924 a year ago. Net loss attributable to common stockholders was $2,136,559 compared to $13,237 a year ago. Net loss per share attributable to common stockholders -diluted was $0.32 compared to $4.04 a year ago. Net loss and comprehensive loss was $2,136,559 compared to net income and comprehensive income of $401,773 a year ago.

Aldeyra Therapeutics, Inc. to Report Q1, 2015 Results on May 13, 2015

Aldeyra Therapeutics, Inc. announced that they will report Q1, 2015 results at 9:00 AM, Eastern Standard Time on May 13, 2015

Aldeyra Therapeutics, Inc., Q1 2015 Earnings Call, May 13, 2015

Aldeyra Therapeutics, Inc., Q1 2015 Earnings Call, May 13, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALDX:US $8.89 USD -0.27

ALDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALDX.
View Industry Companies

Industry Analysis


Industry Average

Valuation ALDX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALDEYRA THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at